Growth Metrics

Amneal Pharmaceuticals (AMRX) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $155.4 million.

  • Amneal Pharmaceuticals' Net Cash Flow rose 44126.27% to $155.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.3 million, marking a year-over-year increase of 104322.83%. This contributed to the annual value of $20.3 million for FY2024, which is 6817.05% down from last year.
  • Amneal Pharmaceuticals' Net Cash Flow amounted to $155.4 million in Q3 2025, which was up 44126.27% from $15.6 million recorded in Q2 2025.
  • Over the past 5 years, Amneal Pharmaceuticals' Net Cash Flow peaked at $155.4 million during Q3 2025, and registered a low of -$172.9 million during Q2 2021.
  • For the 5-year period, Amneal Pharmaceuticals' Net Cash Flow averaged around -$5.3 million, with its median value being -$1.9 million (2022).
  • Per our database at Business Quant, Amneal Pharmaceuticals' Net Cash Flow tumbled by 88595.56% in 2023 and then surged by 113719.31% in 2024.
  • Amneal Pharmaceuticals' Net Cash Flow (Quarter) stood at -$54.1 million in 2021, then decreased by 5.3% to -$56.9 million in 2022, then surged by 105.8% to $3.3 million in 2023, then soared by 1137.19% to $40.8 million in 2024, then surged by 280.81% to $155.4 million in 2025.
  • Its Net Cash Flow stands at $155.4 million for Q3 2025, versus $15.6 million for Q2 2025 and -$49.6 million for Q1 2025.